Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate

NEXT STORY
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
PREV STORY
NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

author_avatar
NASDAQ Market News

FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma

author_avatar
NASDAQ Market News

Insights on the Liquid Handling System Global Market to 2026 – Competitive Analysis and the Impact of COVID-19

author_avatar
NASDAQ Market News